

Date: 11th February, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 11th February, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. 11th February, 2025, has considered and approved the following:

1. Quarterly Standalone Financial Results of the Company for the Quarter and Nine months ended on 31st December, 2024 along with the Limited Review Report thereon.
2. Appointment of Ms. Monica Tanwar as a Company Secretary & Compliance Officer, Key Managerial Personnel of the Company based on the recommendation of Nomination & Remuneration Committee.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD-2/CIR/P/0155 dated 11th November 2024 are given in **Annexure A**.

We wish to inform you that the Board Meeting commenced today at 4.00 p.m. and concluded at 4.45 p.m.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

ANIL
CHAMPAL
AL JAIN

Digitally signed
by ANIL
CHAMPALAL JAIN
Date: 2025.02.11
17:43:07 +05'30'

**Anil Champalal Jain
Managing Director
DIN: 00226137**

Encl: as above

BAJAJ HEALTHCARE LIMITED

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the quarter ended **31 December 2024** and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bajaj Healthcare Limited

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandio & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Yashwant M. Jain

Partner

Membership No. 118782

UDIN : 25118782BMOEKK1852

Place: Mumbai

Date: 11 February 2025

BAJAJ HEALTHCARE LIMITED (CIN No. : L99999MH1993PLC072892)						
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER, 2024						
(Rs. In Lakhs Except for Earnings Per Share)						
Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A. Continuing Operations						
I. Revenue from operations	12,279.40	13,308.92	10,857.25	38,812.99	33,951.89	47,341.79
II. Other Income	237.19	260.67	79.77	583.28	223.29	868.63
III. Total Income (I+II)	12,516.59	13,569.59	10,937.02	39,396.27	34,175.18	48,210.42
IV. Expenses						
(a) Cost of materials consumed	7,267.27	5,503.25	8,664.66	20,661.81	21,379.56	26,442.76
(b) Changes in inventories of finished good and work in progress	(1,175.80)	1,094.67	(3,535.60)	(1,414.14)	(4,272.22)	(965.52)
(c) Employee benefits expense	1,465.29	1,399.35	1,164.88	4,135.23	3,322.86	4,384.54
(d) Finance Costs	550.85	787.60	665.45	2,182.86	2,366.91	2,967.98
(e) Depreciation and amortisation expense	685.05	680.64	735.43	2,038.68	2,032.17	2,761.95
(f) Other expenses	2,558.64	2,859.23	2,609.66	8,363.26	7,498.53	9,853.45
Total Expenses	11,351.30	12,324.74	10,304.48	35,967.70	32,327.81	45,445.16
V. Profit before Exceptional Items and Tax Expense	1,165.29	1,244.85	632.54	3,428.57	1,847.37	2,765.26
VI. Exceptional items (Refer Note g)	-	-	-	-	-	4,432.81
VII. Profit/(Loss) Before Tax	1,165.29	1,244.85	632.54	3,428.57	1,847.37	(1,667.55)
VIII. Tax Expense						
(a) Current tax	-	-	-	-	-	-
(b) Current tax-Earlier Years	-	-	135.64	-	135.64	135.64
(c) Deferred Tax Charge/ (Credit)	(331.27)	410.48	(55.52)	294.99	(55.66)	(370.53)
Total Tax Expenses	(331.27)	410.48	80.12	294.99	79.98	(234.89)
IX. Profit/ (Loss) after Tax from Continuing Operations	1,496.56	834.37	552.42	3,133.58	1,767.39	(1,432.66)
B. Discontinued Operations						
X. Loss before Tax from Discontinued Operations	(117.73)	(83.38)	(722.00)	(313.08)	(7,378.87)	(8,718.96)
XI. Tax Expense / (Credit) of Discontinued Operations	206.71	(195.44)	50.05	(11.27)	(224.60)	(1,772.31)
XII. Profit/(Loss) after Tax from Discontinued Operations	(324.44)	112.06	(772.05)	(301.81)	(7,154.27)	(6,946.65)
XIII. Profit/ (Loss) for the period / year (IX +XII)	1,172.12	946.43	(219.63)	2,831.77	(5,386.88)	(8,379.31)
XIV. Other comprehensive Income						
Continuing Operations						
(i) Items that will not be reclassified to profit or loss	(92.73)	(92.72)	15.05	(278.18)	32.12	(370.92)
(ii) Income tax relating to items that will not be reclassified to profit or loss	23.34	23.34	(3.79)	70.02	(8.09)	93.36
Total Other Comprehensive Income from Continuing Operations	(69.39)	(69.38)	11.26	(208.16)	24.03	(277.56)
Discontinued Operations						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income from Discontinued Operations	-	-	-	-	-	-
XV. Total Comprehensive Income for the Period / Year	1,102.73	877.05	(208.37)	2,623.61	(5,362.85)	(8,656.87)
XVI. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,579.16	1,579.16	1,379.92	1,579.16	1,379.92	1,379.92
XVII. Other Equity						26,456.17
XVIII. EPS (Not Annualised for the Quarter and Period ended)						
Continuing Operations						
(a) Basic (in Rs.)	4.66	2.96	2.00	10.77	6.40	(5.19)
(b) Diluted (in Rs.)	4.65	2.96	2.00	10.76	6.40	(5.19)
Discontinued Operations						
(a) Basic (in Rs.)	(1.01)	0.40	(2.80)	(1.04)	(25.92)	(25.17)
(b) Diluted (in Rs.)	(1.01)	0.40	(2.80)	(1.04)	(25.92)	(25.17)
Total Operations						
(a) Basic (in Rs.)	3.65	3.36	(0.80)	9.73	(19.52)	(30.36)
(b) Diluted (in Rs.)	3.64	3.36	(0.80)	9.72	(19.52)	(30.36)



Note :

a) The above financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 11 February 2025 and subjected to limited review carried out by Statutory Auditors who have expressed unmodified review conclusion.

b) The above unaudited financial results for the quarter and Nine months period ended 31 December, 2024 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS) 34 on "Interim financial Reporting", as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015 as amended.

c) The Company deals in pharmaceuticals products ("formulations and active pharmaceutical ingredients components") which are interlinked and interdependent. Therefore, the Company identified only one reportable segment i.e. Pharmaceuticals.

d) The Board of Directors in their meeting held on 28 June 2023 approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. Approval of shareholders was obtained vide postal ballot. The management continues to classify the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal in accordance with Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Out of the above undertakings/units, one unit situated at plot no. N-92 was sold during the quarter ended 31 March, 2024.

Particulars	Quarter Ended			Period Ended		Year Ended
	31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Total Income (A)	65.40	24.34	83.70	95.88	1,403.81	1,784.51
Total Expenses (B)	183.13	107.72	805.70	408.96	8,782.68	10,503.47
Loss before Tax from Discontinued Operations (C = A - B)	(117.73)	(83.38)	(722.00)	(313.08)	(7,378.87)	(8,718.96)
Tax Expense / (Credit) from Discontinued Operations (D)	206.71	(195.44)	50.05	(11.27)	(224.60)	(1,772.31)
Loss after Tax from Discontinued Operations (E = C - D)	(324.44)	112.06	(772.05)	(301.81)	(7,154.27)	(6,946.65)


e) The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting ("EGM") held on Wednesday, 07 August, 2024 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") approved, the issue of 40,44,852/-Equity Shares at Rs 338/- share to Person(s) belonging to non promoter category on preferential basis and the issue of convertible equity warrants 20,79,409/- at Rs 338/- to Person(s) belonging to promoter category as well as non promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purpose. The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, Board of directors have approved allotment of 39,84,852 no. of equity shares and has also filed the relevant form with Registrar of Companies.

f) The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.

Particulars	Rs.(in Lakhs)
Repayment & prepayment of secured/unsecured loans from bank/NBFC	15,000.00
General corporate purpose	225.90
Total	15,225.90

g) During the previous year, the Company had written off inventories pertaining to certain covid portfolio products owing to continued lower demand, on a conservative basis.

h) Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, which are not material.



Date : 11 February 2025
Place: Thane

For and on Behalf of the Board
For Bajaj Healthcare Limited
ANIL
CHAMPALAL
JAIN

Digitally signed by
ANIL CHAMPALAL
JAIN
Date: 2025.02.11
17:23:45 +05'30'

Mr. Anil C Jain
D.No.: 00226137
Jt. Managing Director



Annexure – A

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD-2/CIR/P/0155 dated 11th November 2024

Appointment of Ms. Monica Tanwar as Company Secretary & Compliance Officer, Key Managerial Personnel of the Company:

Name	Ms. Monica Tanwar
Reason for Change	Appointment as Company Secretary & Compliance Officer, Key Managerial Personnel of the Company
Date of Appointment	With effect from 11 th February, 2025
Brief Profile	Ms. Monica Tanwar is an Associate Member of Institute of Company Secretaries of India (ICSI). She has more than 7 years of experience in dealing with matters of Companies Act and Listing Regulations.
Disclosure of relationship Between Directors (in case appointment of a Director)	Ms. Monica Tanwar is not related to any of the Directors of the Company.